To include your compound in the COVID-19 Resource Center, submit it here.

Biocon endocrine, biosimilars news

Biocon disclosed in its 2010 earnings that it will divest its 78% stake in its AxiCorp GmbH

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE